CeriBell, Inc. (NASDAQ:CBLL) Stock Has Consensus Price Target of $27.00

Shares of CeriBell, Inc. (NASDAQ:CBLL) have received an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $27.00.

Several research firms recently weighed in on CBLL. Canaccord Genuity Group upped their price target on CeriBell from $25.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Raymond James Financial reissued a “strong-buy” rating and issued a $29.00 target price on shares of CeriBell in a report on Thursday, September 3rd. Barclays upgraded CeriBell to a “neutral” rating in a report on Tuesday, August 18th. BTIG Research reaffirmed a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research report on Friday, September 11th. Finally, Weiss Ratings downgraded shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, October 2nd.

CeriBell Trading Down 0.5%

Shares of CBLL traded down $0.14 during trading hours on Tuesday, reaching $25.12. 27,886 shares of the company traded hands, compared to its average volume of 342,903. CeriBell has a 12 month low of $10.85 and a 12 month high of $25.63. The company has a market capitalization of $964.30 million, a price-to-earnings ratio of -14.28 and a beta of 0.94. The company’s fifty day moving average price is $23.52 and its two-hundred day moving average price is $20.46. The company has a quick ratio of 8.79, a current ratio of 9.18 and a debt-to-equity ratio of 0.16.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). CeriBell had a negative return on equity of 44.85% and a negative net margin of 64.73%. The business had revenue of $28.10 million during the quarter, compared to the consensus estimate of $27.28 million. Equities research analysts predict that CeriBell will post -1.96 earnings per share for the current fiscal year.

Insider Buying and Selling

In other CeriBell news, CTO Raymond Woo sold 4,887 shares of the business’s stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $24.38, for a total value of $119,145.06. Following the completion of the transaction, the chief technology officer owned 203,118 shares of the company’s stock, valued at approximately $4,952,016.84. The trade was a 2.35% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CRO Joseph Manni sold 1,361 shares of the company’s stock in a transaction dated Friday, August 21st. The shares were sold at an average price of $24.02, for a total transaction of $32,691.22. Following the transaction, the executive owned 55,956 shares in the company, valued at $1,344,063.12. This represents a 2.37% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 174,905 shares of company stock worth $4,312,995 in the last three months. 17.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Squarepoint Ops LLC purchased a new position in CeriBell during the second quarter valued at approximately $638,000. Wellington Management Group LLP lifted its holdings in shares of CeriBell by 5.5% in the second quarter. Wellington Management Group LLP now owns 87,698 shares of the company’s stock worth $1,706,000 after buying an additional 4,572 shares in the last quarter. Formula Growth Ltd. bought a new position in shares of CeriBell during the second quarter worth $603,000. Bank of America Corp DE bought a new position in shares of CeriBell during the 2nd quarter valued at about $4,619,000. Finally, PDT Partners LLC bought a new position in shares of CeriBell during the 2nd quarter valued at about $1,026,000.

About CeriBell

CeriBell, Inc develops medical technology designed to make electroencephalography (EEG) more accessible in acute-care settings. Its primary product is the Ceribell Rapid Response EEG system, a portable, point-of-care platform that enables clinicians to record and assess brain activity at the bedside, including when evaluating patients for seizures and status epilepticus.

The Ceribell system combines a simplified EEG headband and recording device with software that supports rapid interpretation.